Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Fineline Cube Sep 9, 2026
Company Drug

Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients

Fineline Cube Jan 29, 2024

The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...

Company Deals Drug

Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101

Fineline Cube Jan 29, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...

Company Drug

Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke

Fineline Cube Jan 29, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...

Company Drug

Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 29, 2024

Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...

Company Deals

Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF

Fineline Cube Jan 29, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Company Drug

Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors

Fineline Cube Jan 29, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals Drug

Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong

Fineline Cube Jan 29, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

Formosa Pharmaceuticals Strikes Licensing Deal with Cristália for Ocular Surgery Pain Treatment in Brazil

Fineline Cube Jan 29, 2024

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based...

Company

Lonza Announces Factory Closures in the US and China Amid Global Network Optimization

Fineline Cube Jan 29, 2024

Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...

Company Policy / Regulatory

China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies

Fineline Cube Jan 29, 2024

A bipartisan bill introduced on January 26, 2024, by members of the US House Select...

Company Drug

Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China

Fineline Cube Jan 28, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...

Company Deals

Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center

Fineline Cube Jan 26, 2024

The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology...

Company Deals

Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories

Fineline Cube Jan 26, 2024

Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...

Company Drug

Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia

Fineline Cube Jan 26, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...

Company Drug

Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis

Fineline Cube Jan 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

MSD Partners with Variational AI to Harness Generative AI for Drug Discovery

Fineline Cube Jan 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...

Company Drug

Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin

Fineline Cube Jan 26, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Policy / Regulatory

China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care

Fineline Cube Jan 26, 2024

The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...

Company Drug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors

Fineline Cube Jan 26, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...

Company Drug

Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study

Fineline Cube Jan 26, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...

Posts pagination

1 … 460 461 462 … 718

Recent updates

  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.